Ocrelizumab approved for treatment of primary progressive multiple sclerosis

Written by Roisin Conneely

A license for the drug OCREVUS® (ocrelizumab) has been granted by the European Commission for use in patients with primary progressive multiple sclerosis (PPMS) and the more common relapsing-remitting form (RRMS). Previously, no treatments have been approved for PPMS, the most debilitating type of the disease. Ocrelizumab is a humanized monoclonal antibody designed to target cells expressing CD20 antigens, primarily B cells, which are thought to be major contributors to the damage of axons and myelin. By reducing damage exerted on myelin, it is thought that ocrelizumab may protect against the nerve damage that leads to disability in multiple sclerosis....

To view this content, please register now for access

It's completely free